

AMENDMENT TO THE CLAIMS

1. - 216. (Cancelled)

217. (Currently Amended) A method for inhibiting growth of a cancer cell, the method comprising:

providing a polypeptide comprising an amino acid sequence of a binding domain of a  $\beta$  integrin subunit for ERK2 MAP kinase, said binding domain comprising an amino acid linker sequence that links opposite end regions of the binding domain together, the linker sequence being non-essential for binding of the MAP kinase to said binding domain, and the ~~polypeptide comprising an amino acid sequence of the binding domain being~~ selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYDMASNPLYR (SEQ ID No. 23); and

treating a cancer cell with an effective amount of said polypeptide.

218. (Currently Amended) A method according to claim 217, wherein the polypeptide consists of said binding domain for the ERK2 MAP kinase coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.

219. (Previously Presented) A method according to claim 217, wherein the polypeptide comprises the amino acid sequence RSKAKWQTGTNPLYR (SEQ ID No. 2).

220. (Cancelled)

221. (Previously Presented) A method according to claim 217, wherein the polypeptide is coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.

222 - 224. (Cancelled)

225. (Previously Presented) A method according to claim 217 wherein the cancer cell is a colon cancer cell.

226 - 237. (Cancelled)

238. (Currently Amended) A method according to claim 217, wherein the cancer cell is a cancer cell of a cancer selected from the group consisting of cancer of the lip, tongue, salivary glands, gums, floor ~~and other areas~~ of the mouth, oropharynx, nasopharynx, hypopharynx ~~and other oral cavities~~, oesophagus, stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

239-276. (Cancelled)

277. (Currently Amended) A method according to claim 217286, wherein the polypeptide is consists of between about 5 amino acids and about 25 amino acids in length from said binding domain coupled to a facilitator moiety that facilitates passage

of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.

278-282. (Cancelled)

283. (Currently Amended) A method according to claim 277 wherein the polypeptide is consists of 10 amino acids or 15 amino acids from said binding domain coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell in length.

284. (Cancelled)

285. (Currently Amended) ~~The method of claim 284~~ A method according to claim 286, wherein said polypeptide comprises the amino acid sequence RSKAKNPLYR (SEQ ID No. 3).

286. (New) A method for inhibiting growth of a cancer cell, the method comprising:

providing a polypeptide comprising an amino acid sequence of a binding domain of a  $\beta$  integrin subunit for ERK2 MAP kinase from which an amino acid linker sequence that links opposite end regions of the binding domain together and is non-essential for the binding of the MAP kinase is deleted, the amino acid sequence of the binding domain being selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYDMASNPLYR (SEQ ID NO. 23); and

treating the cancer cell with an effective amount of said polypeptide.

287. (New) A method according to claim 286 in which the polypeptide is coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.